- Assistant Professor, CWRU School of Medicine
Kyunghee Burkitt, DO, PhD, is a medical oncologist at University Hospitals and is board certified in internal medicine.
Dr. Burkitt earned a BS in biochemistry from South Korea and a MS in cancer biology at Michigan State University in East Lansing, Mich. She went on to receive her PhD in cancer biology/toxicology at University of Michigan Cancer Center in Ann Arbor, Mich. After completing postdoctoral fellowships in hematology/oncology at University of Michigan and Michigan State University, she earned her medical degree at Michigan State University College of Osteopathic Medicine.
Dr. Burkitt completed her internal medicine residency training at Michigan State University, Sparrow Hospital in Lansing, Michigan, and a fellowship in medical oncology at the National Cancer Institute.
Dr. Burkitt is very active in research and has been published in numerous manuscripts. Research topics include epigenetic modification, DNA damage response pathways and introduction of novel therapies in clinical trials for head and neck cancer. Her clinical interests include improving response to chemotherapy and radiation therapy and immunotherapy in head and neck cancers.
- Internal Medicine - American Board of Internal Medicine
Fellowship | Hematology/Oncology
Hematology/Oncology - National Cancer Institute (NCI) (2017 - 2020)
Residency | Internal Medicine
Internal Medicine - Sparrow Hospital (2014 - 2017)
Michigan State University College Of Osteopathic Medicine (2009 - 2014)
Michigan State University (1995 - 2000)
University Of Michigan (2007)
Hoseo University (1995)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Kyunghee Burkitt did not disclose any Outside Relationships with Industry.